Literature DB >> 7685203

Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers.

R A DeLa Cadena1, A F Suffredini, J D Page, R A Pixley, N Kaufman, J E Parrillo, R W Colman.   

Abstract

The objective of this study was to determine the role of the kallikrein-kinin system in healthy humans after intravenous administration of either Escherichia coli endotoxin or saline. We studied a total of 18 healthy nonsmoking volunteers, 23 to 38 years old, in an open-label study at the Critical Care Medicine Department, Clinical Center, National Institutes of Health (Bethesda, MD) in which some of the patients served as their own controls. After baseline data collection, the subjects received intravenously either E coli endotoxin (n = 15, 4 ng/kg of body weight) or saline (n = 8, controls). Signs, symptoms, systemic blood pressure, factor XII, plasma prekallikrein (PK), factor XI (FXI), antithrombin III (AT-III), high molecular weight kininogen (HK), and alpha 2-macroglobulin-kallikrein complexes were measured at baseline and 1, 2, 3, 5, and 24 hours after injection of either saline or endotoxin. After infusion of endotoxin, we found the functional plasma levels of FXI decreased at 2 hours (P < .05) and at 5 hours (P < .05). Functional PK was significantly depressed by 2 hours (P < .05), at 5 hours (P < .05), and at 24 hours (P < .01), whereas the PK antigen was only low at 5 hours (P < .05). These changes were accompanied by a significant increase in circulating alpha 2-macroglobulin-kallikrein complexes at 3 hours (P < .05) and 5 hours (P < .01). No significant changes occurred in the plasma levels of factor XII or HK. We concluded that clinical response to intravenous endotoxin in healthy human volunteers is associated with activation of the kallikrein-kinin systems. Further investigation is needed with specific inhibitors of the kallikrein-kinin system to define its primary or secondary role in the endotoxin-mediated reactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685203

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis.

Authors:  R W Colman; R B Sartor; A A Adam; R A DeLa Cadena; A Stadnicki
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat.

Authors:  A Stadnicki; R A DeLa Cadena; R B Sartor; D Bender; C A Kettner; H C Rath; A Adam; R W Colman
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

6.  Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia.

Authors:  M J Mooberry; R Bradford; E L Hobl; F C Lin; B Jilma; N S Key
Journal:  J Thromb Haemost       Date:  2016-04-05       Impact factor: 5.824

7.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  The reduced form of coagulation factor XI is associated with illness severity and coagulopathy in critically-ill septic patients.

Authors:  Ronit Mor-Cohen; Michal Zucker; Colin Grissom; Samuel M Brown; Uri Seligsohn; Robert A Campbell; Antoinette M Blair; Matthew T Rondina
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

Review 9.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.